Explain this page
Arphra AIPlain-English read on Alnylam Pharmaceuticals, Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for ALNY.
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.10% | +0.90% | -0.16% | -9.06% | -36.41% | -25.66% | -3.42% | +52.65% | +106.95% | +298.85% | +4818.97% |
Aftermarket
LiveLast trade
$298.00
23 sh
Bid
$295.00
27 sh
Ask
$299.88
2 sh
Spread
$4.880
Sector & industry today
LiveSectors
- Technology+3.30%
- Basic Materials+0.98%
- Energy+0.83%
- Consumer Cyclical+0.49%
- Industrials+0.25%
- Communication Services+0.13%
- Healthcare-0.65%
- Financial Services-0.80%
- Consumer Defensive-0.84%
- Utilities-1.15%
- Real Estate-1.32%
Top industries (issuer's industry highlighted)
- Biotechnology-2.72%
- Computer Hardware+8.35%
- Software - Infrastructure+7.61%
- Consulting Services+5.28%
- Coal+5.20%
- Manufacturing - Metal Fabrication+4.24%
- Staffing & Employment Services+4.08%
- Gambling, Resorts & Casinos+3.71%
- Broadcasting+3.70%
- Integrated Freight & Logistics+3.68%
- REIT - Healthcare Facilities-3.49%
- Software - Application+3.44%
Fair value
Football field →Weighted blend
$56.66
-80.84% vs spot
Recommendation
Sell
4 of 4 methods
Method spread
0bull4bear
±5% threshold
Analyst PT consensus: $445.67 (+50.75%)
Total assets
$4.97B
Total debt
$1.28B
Cash & equiv
$1.66B
Operating CF
$524.08M
Free cash flow
$465.38M
Buybacks
$0
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Buildmarketbeat.com·May 13, 2026
- New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burdenbusinesswire.com·May 12, 2026
- New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burdenbusinesswire.com·May 12, 2026
- Alnylam to Webcast Presentations at Upcoming Investor Conferencesbusinesswire.com·May 07, 2026
- Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CMbusinesswire.com·May 04, 2026
- Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CMbusinesswire.com·May 04, 2026
- Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growthzacks.com·May 01, 2026
- Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Yearseekingalpha.com·May 01, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $1.17B | $205.99M | $1.51 |
| Q4 Dec 2025 | $1.1B | $186.42M | $1.37 |
| Q3 Sep 2025 | $1.25B | $251.08M | $1.84 |
| Q2 Jun 2025 | $773.69M | -$66.28M | $-0.51 |
| Q1 Mar 2025 | $594.19M | -$57.48M | $-0.44 |
| Q4 Dec 2024 | $593.17M | -$83.76M | $-0.65 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $3.71B | $501.58M | $313.75M | $2.33 | +8.45% |
| FY 2024 | $2.25B | -$176.89M | -$278.16M | $-2.18 | -12.37% |
| FY 2023 | $1.83B | -$282.18M | -$440.24M | $-3.52 | -24.08% |
| FY 2022 | $1.04B | -$785.07M | -$1.13B | $-9.30 | -109.04% |
| FY 2021 | $844.29M | -$708.65M | -$852.82M | $-7.20 | -101.01% |